Full metadata record
DC FieldValueLanguage
dc.creatorTejada-Solis, S. (Sonia)-
dc.creatorDiez-Valle, R. (Ricardo)-
dc.creatorDominguez, P.D. (Pablo Daniel)-
dc.creatorPatiño-García, A. (Ana)-
dc.creatorGonzalez-Huarriz, M. (Marisol)-
dc.creatorFueyo, J. (Juan)-
dc.creatorGomez-Manzano, C. (Candelaria)-
dc.creatorIdoate, M.A. (Miguel Ángel)-
dc.creatorPeterkin, J. (Joanna)-
dc.creatorAlonso, M.M. (Marta M.)-
dc.identifier.citationTejada-Solis, S. (Sonia); Diez-Valle, R. (Ricardo); Dominguez, P.D. (Pablo Daniel); et al. "DNX-2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas: a case report". Frontiers in oncology. 12 (8), 2018, 61es_ES
dc.description.abstractDiffuse intrinsic pontine gliomas (DIPGs) are aggressive glial brain tumors that primarily affect children, for which there is no curative treatment. Median overall survival is only one year. Currently, the scientific focus is on expanding the knowledge base of the molecular biology of DIPG, and identifying effective therapies. Oncolytic adenovirus DNX-2401 is a replication-competent, genetically modified virus capable of infecting and killing glioma cells, and stimulating an anti-tumor immune response. Clinical trials evaluating intratumoral DNX-2401 in adults with recurrent glioblastoma have demonstrated that the virus has a favorable safety profile and can prolong survival. Subsequently, these results have encouraged the transition of this biologically active therapy from adults into the pediatric population. To this aim, we have designed a clinical Phase I trial for newly diagnosed pediatric DIPG to investigate the feasibility, safety, and preliminary efficacy of delivering DNX-2401 into tumors within the pons following biopsy. This case report presents a pediatric patient enrolled in this ongoing Phase I trial for children and adolescents with newly diagnosed DIPG. The case involves an 8-year-old female patient with radiologically diagnosed DIPG who underwent stereotactic tumor biopsy immediately followed by intratumoral DNX-2401 in the same biopsy track. Because there were no safety concerns or new neurological deficits, the patient was discharged 3 days after the procedures. To our knowledge, this is the first report of intratumoral DNX-2401 for a patient with DIPG in a clinical trial. We plan to demonstrate that intratumoral delivery of an oncolytic virus following tumor biopsy for pediatric patients with DIPG is a novel and feasible approach and that DNX-2401 represents an innovative treatment for the disease.es_ES
dc.description.sponsorshipWe acknowledge the funding from The Instituto de Salud Carlos III and Fondos Feder Europeos (PI13/125 and PI16/00066 to MA), the Spanish Ministry of Science and Innovation (IEDI-2015-00638 to MA), and the Basque Foundation for Health Research (BIOEF, BIO13/CI/005). Foundation LA CAIXA (to AG and MA), DOD team science award (to MA, JF, and CG-M).es_ES
dc.subjectMEMS cannulaes_ES
dc.subjectDiffuse intrinsic pontine gliomases_ES
dc.subjectOncolytic viruses_ES
dc.subjectPhase I clinical triales_ES
dc.titleDNX-2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas: a case reportes_ES
dc.description.noteThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.es_ES
dadun.citation.publicationNameFrontiers in oncologyes_ES

Files in This Item:
940.61 kB
Adobe PDF

Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.